Psilocybin for Mental Health

A breakthrough treatment for depression


In the US, the Food and Drug Administration has designated psilocybin a ‘breakthrough treatment’ for depression. We are working to reschedule psilocybin in the UK to support scientific research into psilocybin-assisted therapy.


We are in the midst of a depression epidemic

Millions of people in the UK are suffering from poor mental health, including depression that is resistant to current treatments.


Current treatments are not working

More than half of sufferers of depression in the UK don’t find benefits from typical medications.

Robin-Carhart-Harris 10.04.55.png

Psilocybin has shown huge promise

Psilocybin-assisted therapy is one of the most promising innovations for the treatment of depression seen for decades, with greater than 70% long-term efficacy.


Research is hindered by its restrictive Schedule 1 status

The UK has contributed significantly to the field of psilocybin-assisted therapy. However, scientists are currently being held back by psilocybin’s Schedule 1 status, which makes research in the UK ten times more expensive than it could be.


We are working with politicians and mental health professionals to support UK research by rescheduling psilocybin to Schedule 2. This would help lift restrictions on research while continuing to appropriately mitigate risk.


 Backed by leading drug policy organisations…


…and a cross-party coalition of MPs

Caroline Lucas MP  Green

Caroline Lucas MP

Crispin Blunt MP  Conservative

Crispin Blunt MP

Clive Lewis MP  Labour

Clive Lewis MP

Norman Lamb MP  Liberal Democrat

Norman Lamb MP
Liberal Democrat

Jeff Smith MP  Labour

Jeff Smith MP


Learn more about Imperial College London’s new
Centre for Psychedelic Research


The UK has the chance to become a world leader in a breakthrough treatment for depression

The UK government now has an opportunity to expedite groundbreaking new research that could revolutionise the treatment of depression by rescheduling psilocybin.